Biricodar

Drug Profile

Biricodar

Alternative Names: Biricodar dicitrate; Incel; VX 710; VX 710-3

Latest Information Update: 20 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Chemosensitisers; Piperidines; Pyridines
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections; Breast cancer; Liver cancer; Ovarian cancer; Prostate cancer; Sarcoma; Small cell lung cancer

Most Recent Events

  • 18 Feb 2005 A preclinical study has been added to the Bacterial Infections pharmacodynamics section
  • 30 Nov 2004 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 21 Jun 2001 Vertex is seeking collaborative partners to further develop and commercialise biricodar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top